Abstract: The present invention relates to a sensomotoric hand therapy device comprising a flexible shell having a first leg portion configured to accommodate fingers of a hand of a patient, a second leg portion configured to accommodate a thumb of the patient and a U-shaped portion configured to accommodate a metacarpus of the patient. The device further comprises a first reinforced member connected to a distal end region of the first leg portion of the shell, a second reinforced member connected to a distal end region of the second leg portion of the shell and a third reinforced member connected to and reinforcing the U-shaped portion of the shell. Further, the device comprises a movement mechanism defining a course and resistance of movement of the first reinforced member and the second reinforced member relative to the third reinforced member; and to a respective hand therapy system and hand training method.

Abstract: The present invention relates to a compound of formula (A)

Abstract: A device for in-vitro modelling in-vivo tissues of organs that includes a device for in-vitro modelling in-vivo tissues of organs, the device including an open access chamber, a perfusion channel, and a culturing membrane dividing the access chamber from the perfusion channel, wherein the culturing membrane is porous and flexible and/or elastic.

Abstract: The present invention relates to a non-agonist ligand, particularly an antibody, that specifically binds to LIGHT or its receptor LT?R thereby interrupting the interaction of LIGHT with LT?R for use in treatment of a haematologic malignancy.

Abstract: The invention relates to a method for the preparation of peptides via solid-phase peptide synthesis and particularly to a method of deprotecting of an Fmoc protected amino acid building block linked to a resin R-AA-(AA)n-PF.

Abstract: The present invention relates to compounds of formula 1 or 2, wherein R1 and R3 are purine or a purine analog and R2 and R4 are a small functional group. The invention also relates to intermediates of the synthesis of compounds of formula 1 or 2. Compounds of formula 1 or 2 are Janus kinase inhibitors and thus useful in the treatment of a disease, particularly an autoimmune disease, cancer, Alzheimer's disease or useful in preventing the rejection of an allograft or xenograft.

Abstract: A method for generating 2?-refocusing pulses for magnetic resonance spectroscopy (MRS), and for performing spectral editing of MRS data using differential custom bandpass editing. Acquisition may be performed using echo-planar spectroscopic imaging (EPSI), for example. The 2?-refocusing is achieved using chemical-shift-selective adiabatic 2?-refocusing pulses, without spatial-selective (e.g. slice-selective) refocusing. The spectral editing method uses two data sets with different bandpass (‘full’ and ‘partial’) editing spectra, and takes the difference of the two edited spectra. The approach lends itself to 3D spectroscopy at B0 of 7 T or higher, and permits whole brain J-coupled metabolite editing (e.g. 2HG or GABA), with greatly reduced specific absorption rate, shorter repetition time, minimal chemical-shift displacement artefacts (CDSAs), robustness to B0-inhomogeneity and indifference to B1+-inhomogeneity compared with existing spatial-selective methods, such as MEGA.

Abstract: The present invention relates to adeno-associated virus capsid polypeptide sequences and their use in therapeutic transgene delivery to the eye and potentially other tissues.

Abstract: The invention relates to a bacterial cell comprising a Cas1 RT fusion protein, a Cas2 protein and a CRISPR direct repeat (DR) sequence, wherein an RNA polymerase promoter in addition to the leader sequence is associated with the DR sequence. The invention further relates to a composition comprising two bacterial cell populations, each comprising a Cas1 RT fusion protein and Cas2 protein. The two cell types contain different versions of a CRISPR direct repeat (DR) sequence. The invention further relates to methods for analysis of transcription recording events of bacteria having passed through a subject's intestine, to assign a probability to the subject having a condition, such as malnutrition or inflammation of the intestine.

Abstract: The present invention relates to a non-agonist ligand, particularly an antibody, that specifically binds to LIGHT or its receptor LT?R thereby interrupting the interaction of LIGHT with LT?R for use in treatment of a haematologic malignancy.

Abstract: An urinary pumping device for generating a fluid flow through a urethra of a patient includes an activation arrangement configured to induce intermittent compression and release of the urethra, and a mounting structure to mount and unmount the activation arrangement to a body of the patient. The mounting structure is configured to position the activation arrangement on the body of the patient such that the urethra of the patient can be intermittently compressed and released by the activation arrangement.

Abstract: A culturing membrane comprising a support provided by a mesh with holes filled with extracellular matrix proteins, as well as a method of producing a culturing membrane made of components found in a basal membrane, comprising the steps of using a mesh having holes; and providing a solution with the components found in the basal membrane on the mesh.

Abstract: A facility for the production of radionuclides based photonuclear irradiation, comprising: an electron accelerator (1), producing an electron beam (2); a converter target assembly (21) with a converter target (20) that converts the electron beam (2) to Bremsstrahlung photons (15); a production target (17), irradiated by the Bremsstrahlung photons (15) and thereby producing said radionuclides.

Abstract: The present invention relates to a method for preparing a radioactive polymerizable solution and the solution per se. The solution is prepared by using a cationic radionuclide with a half-life >5 d that is dissolved in an aqueous solution. The radionuclide is extracted into an organic solvent or monomer solution by using a lipophilic ligand for forming a radioactive complex. The ligand is characterized by a ?2:1 ratio of carbon and/or silicon atoms to specific heteroatoms. If an organic solvent is used for extraction, the organic phase obtained is subsequently diluted in a monomer solution to obtain the radioactive polymerizable solution. The invention further relates to the use of said solution in a method for preparing a radioactive object such as a phantom for medical imaging and the object per se.

Abstract: The invention relates to a computer program that when executed on a computer causes a system to execute a method, particularly a computer-implemented method for determining a plurality of functional ocular parameters, with the system comprising an optical system (3) with a display system (4) that is configured to independently project a visual stimulus to a left and a right eye of a test person, an eye-tracking system (5) configured to record a gaze direction (100) and a pupil size (102) of the left as well as the right eye, said computer (2) being configured to control the optical system (3) and to receive recorded data from the eye-tracking system (5), wherein an afferent pupillary defect (APD), particularly a relative afferent pupillary defect (RAPD) is determined from a first trial session consisting of a sequence of first kind of stimuli presented to the left and the right eye of the test person eyes with the display system (4), and wherein a visual field (400) is determined from a second trial session c

Abstract: The present invention relates to a pharmaceutical nucleic acid agent capable of downregulating or inhibiting the activity of the minor spliceosome (MiS) for use in treatment or prevention of recurrence of cancer. The invention also relates to a method for the diagnosis of cancer.

Abstract: The invention relates to a computer program causing a system with a computer to execute a method, particularly a computer-implemented method for determining at least one functional ocular parameter, namely a visual acuity, wherein the system comprises an optical system with a display system that is configured to independently project a visual stimulus to a left and a right eye of a test person, wherein the visual stimulus comprises a plurality of patches arranged on a background, an eye-tracking system configured to record a gaze direction of the left as well as the right eye, a computer configured to control the optical system and to receive recorded data from the eye-tracking system, the method comprising at least the steps of: executing a trial session for determining the visual acuity, wherein the trial session comprises a plurality of the visual stimuli that are presented, with the optical system to the left and/or the right eye of the test person; recording data during the trial session comprising infor

Abstract: The present invention relates to a medical device (1) for determining an oxygen saturation in a tissue of a subject, comprising: a sensor (2) comprising a flexible textile (10) comprising a plurality of first optical fibers (11) and a plurality of second optical fibers (12), wherein the first optical and second optical fibers (11, 12) each comprise a first end (11a, 12a) and a second end (11b, 12b), wherein the sensor (2) further comprises a first light generating unit (3) configured to generate and couple light of a first wavelength into the first ends (11a) of the first optical fibers (11) and to generate and couple light of a second wavelength into the second ends (12a) of the first optical fibers (11), the first wavelength being different from the second wavelength, wherein the respective first optical fiber (11) is configured to emit light via a light emitting section (21) of the respective first optical fiber (11) to irradiate tissue of the subject, the light emitting section (21) being arranged between

Abstract: Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.

Abstract: The present invention relates to a magnetic field exposure system for use in exposing organic cells, cellular tissue or at least a part of a subject to a low frequency magnetic field. The system includes a magnetic field generator and amplifier feeding one or more electromagnetic coils configured to produce a magnetic field that varies according to an amplitude modulated signal with a carrier frequency of from 360 to 450. Hz, wherein the modulation frequency is from 0.5 to 100. Hz; and wherein the MF has a field strength of from 0.5 to 250 ?T.